Gene · 1642
DDB1: damage specific DNA binding protein 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. DDB1: damage specific DNA binding protein 1. Genes, record 1642. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1642
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q16531 | DNA damage-binding protein 1 | 1,140 | 213 | Ensembl, GeneID, HGNC |
Source UniProt
Patents31
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 4100 | Q16531 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 4100 | Q16531 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 5848 | Q16531 | Espacenet |
| US 11504404 B2 | 2022-11-22 | 174 | Q16531 | Espacenet |
| US 11459613 B2 | 2022-10-04 | 22 | Q16531 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 22420 | Q16531 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 2502 | Q16531 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 125391 | Q16531 | Espacenet |
| JP 2021169490 A | 2021-10-28 | 260 | Q16531 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 2937 | Q16531 | Espacenet |
1 to 10 of 31
See all 31 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| IBERDOMIDE | CHEMBL3989927 | CRL4(CRBN) E3 ubiquitin ligase modulator | MODULATOR | ChEMBL |
| LENALIDOMIDE | CHEMBL848 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | INHIBITOR | ChEMBL |
| LENALIDOMIDE | CHEMBL848 | CRL4(CRBN) E3 ubiquitin ligase modulator | MODULATOR | ChEMBL |
| LENALIDOMIDE HYDROCHLORIDE MONOHYDRATE | CHEMBL6068337 | CRL4(CRBN) E3 ubiquitin ligase modulator | MODULATOR | ChEMBL |
| POMALIDOMIDE | CHEMBL43452 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | INHIBITOR | ChEMBL |
| THALIDOMIDE | CHEMBL468 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | INHIBITOR | ChEMBL |
Trials1,695
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | LENALIDOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | IBERDOMIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | LENALIDOMIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07585747 | LENALIDOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07569757 | POMALIDOMIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07562022 | LENALIDOMIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07555938 | POMALIDOMIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07532525 | POMALIDOMIDE | PHASE1 | ClinicalTrials.gov | |
| NCT07523737 | POMALIDOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07505849 | LENALIDOMIDE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 1,695
See all 1,695 trialsNIH grants2,290
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | DDB1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 22 | 2025 |
| R01CA214608 | The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase | 17 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 14 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 14 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 13 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 13 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 13 | 2025 |
| P30CA014599 | Cancer Center Support Grant | 11 | 2025 |
| R01CA218278 | Degrading therapeutically important kinases using small molecules | 11 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 10 | 2025 |
1 to 10 of 2,290Source NIH's project files
See all 2,290 nih grantsPapers3,503
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Structural basis of diverse substrate recruitment by the HIV-1 Vpr-hijacked CRL4(VprBP) E3 ligase. | PLoS Pathog | 2026 | 42821551 | PubTator, text mining | PubMed |
Lipid Conjugation of a Photoprotective Meadowfoam (Limnanthes alba) Glucolimnanthin Derivative Reduces Cytotoxicity, Attenuates UV-Induced DNA Damage and Activates DNA Repair in Human Keratinocytes Following UV Radiation. | Biomolecules | 2026 | 42650817 | PubTator, text mining | PubMed |
| Ubiquitin-dependent control of PD-L1 nuclear translocation by DDB1 dictates anti-PD-1 response. | Sci Bull (Beijing) | 2026 | 42608270 | PubTator, text mining | PubMed |
| HBx Downregulates TFEB via the CUL4A/CUL4B-DDB1 Axis to Disrupt Lysosomal Function in Hepatocellular Carcinoma Cells. | Cells | 2026 | 42505369 | PubTator, text mining | PubMed |
| CRISPR/Cas9 screen identifies DCAF4 as a novel protector of hepatocellular carcinoma against brachytherapy via stress granule-dependent NRF2 activation. | Cell Death Dis | 2026 | 42449099 | PubTator, text mining | PubMed |
| Synthesis of Nitazoxanide Derivatives as Potent and Orally Available HBx-DDB1 Inhibitors against Hepatitis B Virus. | ACS Med Chem Lett | 2026 | 42445001 | PubTator, text mining | PubMed |
| DCAF13 is associated with pancreatic ductal adenocarcinoma progression and p53-related signaling in TP53-mutant cells. | Biochem Biophys Res Commun | 2026 | 42361739 | PubTator, text mining | PubMed |
| UV-DDB as a Dynamic Regulator Linking Base Excision and Nucleotide Excision Repair via AAG Interaction. | Int J Mol Sci | 2026 | 42353235 | PubTator, text mining | PubMed |
| Beyond KEAP1: The Context-Specific NRF2 Partner Code in Disease and Therapy. | Antioxidants (Basel) | 2026 | 42352065 | PubTator, text mining | PubMed |
| Structural basis for selective and potent degradation of IRAK4 by KT-474. | Nat Commun | 2026 | 42336816 | PubTator, text mining | PubMed |
1 to 10 of 3,503
See all 3,503 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1642
GET https://conductscience.org/api/genes/v1/1642/patents?page=2